免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用

doi:10.3760/cma.j.cn371439-20220511-00111

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (9): 568-571.doi: 10.3760/cma.j.cn371439-20220511-00111

免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用

史英侠¹, 胡莉钧², 于静萍³()

¹大连医科大学研究生院,大连 116000
²南京医科大学附属常州市第二人民医院放疗科,常州 213000
³上海中医药大学附属曙光医院放疗科,上海 201203

收稿日期:2022-05-11 修回日期:2022-05-24 出版日期:2022-09-08 发布日期:2022-10-21
通讯作者: 于静萍 E-mail:yujingping700420@sina.com
基金资助:
常州市科技计划(CZ20210030);南京医科大学科技发展基金(2017NJMUZD39)

Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer

Shi Yingxia¹, Hu Lijun², Yu Jingping³()

¹Graduate School of Dalian Medical University, Dalian 116000, China
²Department of Radiation Oncology, Changzhou No.2 People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213000, China
³Department of Radiation Oncology, Shuguang Hospital, Affiliated Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received:2022-05-11 Revised:2022-05-24 Online:2022-09-08 Published:2022-10-21
Contact: Yu Jingping E-mail:yujingping700420@sina.com
Supported by:
Changzhou Science and Technology Program(CZ20210030);Science and Technology Development Fund Project of Nanjing Medical University(2017NJMUZD39)

摘要/Abstract

摘要：

大部分早期宫颈癌患者可通过手术或同步放化疗获得良好的疗效,然而对于复发或转移性宫颈癌患者,可选择的治疗方案较少且预后较差。近年来,随着肿瘤免疫治疗的发展,尤其是以程序性死亡蛋白-1（PD-1）及其配体（PD-L1）和细胞毒性T淋巴细胞相关蛋白-4（CTLA-4）为靶点的免疫检查点抑制剂（如帕博利珠单抗、纳武利尤单抗、伊匹木单抗）,均已在复发或转移性宫颈癌的治疗中取得了突破性的进展。

关键词: 宫颈肿瘤, 免疫疗法, 免疫检查点抑制剂

Abstract:

Most early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy. However, for patients with recurrent, metastatic cervical cancer, the available effective treatment is rare and the prognosis is poor. In recent years, with the development of immunotherapy, especially immune checkpoint inhibitors targeting programmed death-1 （PD-1） and its ligand （PD-L1） and cytotoxic T-lymphocyte associated protein-4 （CTLA-4）, such as pembrolizumab, nivolumab, ipilimumab, has made breakthrough progress in the treatment of recurrent or metastatic cervical cancer.

Key words: Uterine cervical neoplasms, Immunotherapy, Immune checkpoint inhibitors

史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.

Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 568-571.

参考文献 17

[1]	Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities[J]. J Natl Med Assoc, 2020, 112(2): 229-232. DOI: 10.1016/j.jnma.2020.03.002. doi: S0027-9684(20)30043-2 pmid: 32278478
[2]	Liontos M, Kyriazoglou A, Dimitriadis I, et al. Systemic therapy in cervical cancer: 30 years in review[J]. Crit Rev Oncol Hematol, 2019, 137: 9-17. DOI: 10.1016/j.critrevonc.2019.02.009. doi: S1040-8428(18)30340-8 pmid: 31014518
[3]	Wendel Naumann R, Leath CA 3rd. Advances in immunotherapy for cervical cancer[J]. Curr Opin Oncol, 2020, 32(5): 481-487. DOI: 10.1097/CCO.0000000000000663. doi: 10.1097/CCO.0000000000000663 pmid: 32740092
[4]	Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ⅰb KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36): 4035-4041. DOI: 10.1200/JCO.2017.74.5471. doi: 10.1200/JCO.2017.74.5471
[5]	Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265. doi: 10.1200/JCO.18.01265
[6]	Cohen AC, Roane BM, Leath CA. Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy[J]. Drugs, 2020, 80(3): 217-227. DOI: 10.1007/s40265-019-01249-z. doi: 10.1007/s40265-019-01249-z pmid: 31939072
[7]	Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. DOI: 10.1056/NEJMoa2112435. doi: 10.1056/NEJMoa2112435
[8]	中华医学会妇科肿瘤学分会. 妇科肿瘤免疫检查点抑制剂临床应用指南[J]. 协和医学杂志, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683. doi: 10.12290/xhyxzz.2021-0683
[9]	Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durva-lumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018, 379(24): 2342-2350. DOI: 10.1056/NEJMoa1809697. doi: 10.1056/NEJMoa1809697
[10]	Lin AJ, Dehdashti F, Massad LS, et al. Long-term outcomes of cervical cancer patients treated with definitive chemoradiation following a complete metabolic response[J]. Clin Oncol (R Coll Radiol), 2021, 33(5): 300-306. DOI: 10.1016/j.clon.2021.01.010. doi: 10.1016/j.clon.2021.01.010 pmid: 33581976
[11]	Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase Ⅰ/Ⅱ CheckMate 358 trial[J]. J Clin Oncol, 2019, 37(31): 2825-2834. DOI: 10.1200/JCO.19.00739. doi: 10.1200/JCO.19.00739 pmid: 31487218
[12]	Da Silva DM, Enserro DM, Mayadev JS, et al. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)[J]. Clin Cancer Res, 2020, 26(21): 5621-5630. DOI: 10.1158/1078-0432.CCR-20-0776. doi: 10.1158/1078-0432.CCR-20-0776
[13]	Lheureux S, Butler MO, Clarke B, et al. Association of ipili-mumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma[J]. JAMA Oncol, 2018, 4(7): e173776. DOI: 10.1001/jamaoncol.2017.3776. doi: 10.1001/jamaoncol.2017.3776
[14]	Anipindi M, Smith RJ, Gilani M. Case report: immune checkpoint inhibitors as a single agent in the treatment of metastatic cervical cancer[J]. Front Oncol, 2022, 12: 856944. DOI: 10.3389/fonc.2022.856944. doi: 10.3389/fonc.2022.856944
[15]	O'Malley DM, Randall LM, Jackson CG, et al. RaPiDS (GOG-3028): randomized Phase Ⅱ study of balstilimab alone or in combination with zalifrelimab in cervical cancer[J]. Future Oncol, 2021, 17(26): 3433-3443. DOI: 10.2217/fon-2021-0529. doi: 10.2217/fon-2021-0529 pmid: 34409858
[16]	Feng CH, Mell LK, Sharabi AB, et al. Immunotherapy with radio-therapy and chemoradiotherapy for cervical cancer[J]. Semin Radiat Oncol, 2020, 30(4): 273-280. DOI: 10.1016/j.semradonc.2020.05.003. doi: 10.1016/j.semradonc.2020.05.003
[17]	Dyer BA, Feng CH, Eskander R, et al. Current status of clinical trials for cervical and uterine cancer using immunotherapy combined with radiation[J]. Int J Radiat Oncol Biol Phys, 2021, 109(2): 396-412. DOI: 10.1016/j.ijrobp.2020.09.016. doi: 10.1016/j.ijrobp.2020.09.016

免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用

Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 17

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[4]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[5]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[6]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[7]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[8]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[11]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[12]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[13]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[14]	陈欣祎, 翁一鸣, 魏家燕, 王劲松, 彭敏. 免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 553-557.
[15]	邓隽军, 赵大勇, 李淼. 免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568.